Cancel Preloader

IndianGOVT approves usage of Remdesivir drug for COVID-19

 IndianGOVT approves usage of Remdesivir drug for COVID-19

New Delhi: Government of India approved on Tuesday the use of antiviral drug Remdesivir to treat severe Coronavirus cases. Primarily manufactured by California’s Foster City based Gilead Sciences Inc., Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials and therefore, currently stands at the forefront of global struggle to combat the spread of Novel Coronavirus contagion infection.

Approved on Monday, the intravenous drug can be administred into critical Coronavirus patients, from Tuesday onward anywhere in India.

“(Remdesivir) is approved on June 1 under emergency use with condition for five dose administration,” the (DCGI) Drugs Controller General of India was quotes as saying by the News agency Reuters in an e-mailed response.

Earlier, the drug had received an emergency authorisation, first in the United States and then in Japan.

“DCGI has granted regulatory approval of (remdesivir) for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalised with severe disease,” the DCGI continued explaining to the Reuters in an e-mailed response.

Gilead had stated last week that Remdesivir showed modest benefit in patients with moderate COVID-19 given a five-day course, while those who received it for 10 days in the study did not fare that well. That’s why authorities worldwide have recommended it’s usage only in the severe Coronavirus cases.

In India, the DCGI too decided against the ten-days usage of the drug. As for maintaining the steady supply for this currently sought-after COVID-19 drug, Gilead signed non-exclusive licensing pacts last month with five generic drugmakers in India and Pakistan.

“While there is currently limited global supply of remdesivir, the company anticipates new supply of the drug to start to become available in July,” Gilead spokesperson was quoted as saying by Reuters.

Leave a Reply

Your email address will not be published. Required fields are marked *